Google
FBIO Stock Price & Analysis — Fortress Biotech Inc (Healthcare >> Biotechnology)
FBIO FAQ
What is FBIO's P/E ratio?
Fortress Biotech Inc (FBIO) currently trades at a P/E ratio of 0.69.
What is FBIO's ROE?
Fortress Biotech Inc reports a Return on Equity (ROE) of 78.77%.
What is FBIO's dividend yield?
Fortress Biotech Inc offers a dividend yield of 0.00%.
What is FBIO's Quality Score?
Our AI rates FBIO's overall financial quality at 77 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy FBIO?
Our AI Timing Score for FBIO is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does FBIO belong to?
Fortress Biotech Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
FBIO AI Analysis Summary
Our AI summary for FBIO: Fortress Biotech Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.69, ROE of 78.77%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 2.79
Price
0.07
(2.57%)
Day Change
|
|
|---|
FBIO, the overall quality is good ( Quality = 77) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not good , and ability to make profit is good , ...
| Quality Factors |
|
64% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
532
|
| Magic Formula Rank by ROE |
532
|
| Magic Formula Rank by ROIC |
409
|
| Price | 2.79 |
| PBV / Sector |
0.45 / 44,105.10
GREAT
|
| Earning Per Share | 3.95 |
| PE / Sector |
0.69 / 19.37
GREAT
|
| PEG or PE/Growth / Sector |
-0.01 / 1.06
|
| Average 1M Daily Value |
2.32 M
GREAT
|
| Average 1W Daily Value |
2.90 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
72% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-06 07:59:58 |
| Symbol | FBIO |
| Name | FORTRESS BIOTECH INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 33.22 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 90.36 / 9,702.21 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
Phone: 781 652 4500
Website: https://www.fortressbiotech.com
Employees: 78
Sector: Healthcare >> Biotechnology
Description: Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap